Vivos Therapeutics
VVOS
23 hedge funds and large institutions have $2.13M invested in Vivos Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
67% more capital invested
Capital invested by funds: $1.27M → $2.13M (+$858K)
21% more funds holding
Funds holding: 19 → 23 (+4)
2.32% more ownership
Funds ownership: 6.83% → 9.15% (+2.3%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$906K |
| 2 |
SWIG
Strategic Wealth Investment Group
Louisville,
Kentucky
|
+$453K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$221K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$188K |
| 5 |
Renaissance Technologies
New York
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$647K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$118K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$64.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$20.9K |
| 5 |
Raymond James Financial
St Petersburg,
Florida
|
-$234 |
VVOS Hedge Fund Activity: Q3 2025 in Review
23 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2025, worth a combined $2.13M — up 67% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VVOS positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Connective Capital Management, opening a new position worth an estimated $906K. The largest seller was UBS Group, cutting an estimated $647K.
- 23 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2025, up from 19 in Q2 2025.
- Funds reported $2.13M of Vivos Therapeutics stock for Q3 2025, up 67% quarter-over-quarter.
- 7 funds opened new Vivos Therapeutics positions in Q3 2025 and 3 closed out, a net change of +4 holders.
- The largest Vivos Therapeutics buyer in Q3 2025 was Connective Capital Management, an estimated $906K added.
- The largest Vivos Therapeutics seller in Q3 2025 was UBS Group, an estimated $647K sold.
Based on aggregated 13F filings for Q3 2025.